Work Group biographic and disclosure information: A.X.G. (Work Group Cochair) is Professor of Medicine, Epidemiology and Biostatistics at Western University in London, Ontario, Canada. He practices nephrology at the London Health Sciences Centre where he is also the Director for Living Kidney Donation. He is the Province of Ontario Medical Lead for Access to Kidney Transplantation and Living Donation. A.X.G. is a member of the Canadian Living Donor Advisory Committee for Canadian Blood Services and he chairs the Donor Nephrectomy Outcomes Research (DONOR) Network. He currently holds a Clinician Investigator Award from the Canadian Institutes of Health Research (CIHR) and the Dr. Adam Linton Chair in Kidney Health Analytics. A.X.G. has received partnership funding from Astellas for CIHR funded research in living kidney donation. Grant/Research Support: Astellas.
K.L.L. (Work Group Cochair) is Professor of Medicine with tenure at Saint Louis University, with positions in Internal Medicine/Nephrology and the Center for Abdominal Transplantation. K.L.L. earned her MD degree from Stanford University, and also completed an Internal Medicine residency, Nephrology fellowship, and master’s degree in Clinical Epidemiology at Stanford. She completed additional fellowship training focused in Transplant Epidemiology and Outcomes at Washington University, and earned a PhD from the Saint Louis University School of Public Health. K.L.L. oversees the evaluation, care and follow-up of living kidney donors at Saint Louis University. She is also a clinical scientist whose work is grounded in novel application and integration of national registries, administrative claims data, and other electronic health information sources to address topics in transplant-related epidemiology, outcomes and policy. To date she has coauthored more than 170 peer-reviewed articles and is the first author of the UpToDate chapters on living donor evaluation and risks. She also edits the living kidney donation section of Current Transplantation Reports. K.L.L.’s professional service activities include participation as regional representative, vice chair and now chair of the United Network for Organ Sharing (UNOS) Living Donor Committee. She is a steering committee member of the Scientific Registry of Transplant Recipients (SRTR) Living Donor Collective, and is a member of the American Society of Nephrology (ASN) Quality, Safety, and Practice Committee. She has served as director of the National Kidney Foundation (NKF) Spring Clinical Meeting transplant physicians’ program and kidney transplant course (2016 and 2017). Grants/Research Support: NIH. Ownership: XynManagement, Inc.
P.L.A. is Professor Emerita of Nephrology and Transplantation at the Wake Forest University School of Medicine (WFUSM). She served for 30 years as transplant nephrologist at the WFUSM renal/pancreas transplant program. She is a former president of the Southeastern Organ Procurement Foundation (SEOPF) and of the UNOS, and was a founding member of the American Society of Transplant Physicians which subsequently merged with the American Society of Transplant Surgeons to become the American Society of Transplantation. In 2013, she received the Senior Achievement Award from the AST. P.L.A. reported no relevant financial relationships.
J.A. has been staff member of the Transplantation Department at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMNSZ) in Mexico City since 1989 and Head of the Department from 1995 to May 2012, where she also received her training in Internal Medicine, General Surgery and Kidney Transplant Surgery. She graduated from Universidad Autónoma de Guadalajara, Mexico and is now Professor of Transplantation at Universidad Nacional Autónoma de México. J.A. trained a significant number of residents in kidney transplantation, many of whom are presently heads of various government transplant programs across Mexico. J.A. has served as president of the Mexican Institute for Nephrological Research and of the Medical Association of the INCMNSZ, and vice president of the Latin America and the Caribbean Society of Transplantation. She is also a founding member of the Mexican Society of Transplantation and an active member of the National System of Investigators. J.A. is a member of the AST’s Women’s Health Community of Practice and Member of The Transplantation Society Steering Committee of Women in Transplantation. She was an honorary member of the American Surgical Association in 2012, and is President-elect for the Mexican Society of Transplantation 2018 to 2019. Her fields of research investigation are varied which include clinical and epidemiological aspects of kidney transplantation. She has received funds from the National Council on Science and Technology. During her professional career she has authored more than 120 articles and book chapters in the field of transplantation, and has participated in numerous national and international meetings. Speaker: Janssen-Cilag; Pfizer.
M.A.B. is the Chief of Dialysis and Transplantation Department, Urology-Nephrology Center, Mansoura University, Egypt (2010-2013), vice president of Arab Society of Nephrology and Renal Transplantation, a council member of both Egyptian Society of Nephrology and Transplantation (2010-2012) and the Middle East Society for Organ Transplantation (2008-2012) for which he maintains his responsibility for its fellowship program in Egypt and served as a consultant for World Health Organization (WHO) in nephrology (1997, 1999). He has been an active member in many committees including accreditation committee of AST (2008-2009), supreme committee of nephrology, national committee for prevention of renal diseases, and Istanbul declaration custodian group Cairo (2010). M.A.B. received many awards from the Egyptian Academy of research and technology, including Dr. Fakhry prize (1994), National Encouragement prize (1999), Mansoura Medical prize (2006) and prize of excellence in Medical science (2010). He started transplantation programs in many Arab countries and authored approximately 200 publications. He is also a peer reviewer and editorial board member for many international journals such as Clinical Transplantation, Clinical and Experimental Transplantation, Eastern Mediterranean Health Journal and Indian Journal of Nephrology. M.A.B. is also an abstract reviewer for many world congresses of nephrology and transplantation. Dr. Bakr reported no relevant financial relationships.
L.G. received his MD from the University of Padua in 1991. He completed his postdoctoral training at Harvard Medical School in the laboratory of Immunogenetics and Transplantation under the mentorship of Drs Charles Carpenter and Mohamed Sayegh from 1992 to 1995. He then completed his residency in Internal Medicine at the Brigham and Women’s Hospital, and his Renal Fellowship at the Brigham and Women’s Hospital and the Massachusetts General Hospital in 1999. Dr. Gallon later moved to Northwestern University as Assistant Professor of Medicine in 2000 and became Medical Director of the Comprehensive Transplant Center, as well as the Director of the Renal Transplant Fellowship in 2004. In 2004, he received the Council’s Clinical Science Faculty Award from the AST and was appointed as full Professor of Medicine at Northwestern University in 2013. L.G. served as a member of the AST awards and grants committee from 2007 to 2010 and is currently a member of the AST Renal Accreditation Committee and the AST Transplantation and Immunology Research Network Scientific review Committee. L.G.'s research has focused on immunobiology of transplantation, with a particular emphasis on the impact of currently used immunosuppression and new immunosuppressive agents on immune cell subpopulations, chronic renal allograft rejection and induction of tolerance in renal transplant candidates. He is also actively studying recurrent FSGS postkidney transplant. L.G. was able to confirm that the pathogenesis of primary FSGS in humans is due to a circulating factor and that there is full reversibility of histopathologic findings of FSGS and a rapid recovery of allograft function after retransplantation. L.G. has received support from AST, National Institutes of Health (NIH), and pharmaceutical companies and he has published over 75 peer review publications and trained 16 clinical renal transplant fellows. Grant/Research Support: Novartis; NIH. Speaker: Alexion.
C.A.G. graduated from the College of St. Catherine in St. Paul, Minnesota in 1975 where she received a bachelor’s degree in Nursing. Her entire nursing career has been spent in the care of transplant patients. She began in 1975 as a staff nurse on the transplant unit of the University of Minnesota hospital, then in 1991 as a transplant coordinator. She has worked with potential living organ donors at the University of Minnesota Medical Center (UMMC), Fairview and has experience working with both adult and pediatric kidney and pancreas transplant patients. C.A.G. has been involved in the initiation of and continued development of the nondirected kidney donor program at UMMC. From 2009 to 2012, she worked as the Clinical Director-Transplant at the UMMC program, then as the Director of Quality, Regulatory and Clinical Practice for the transplant program. From 2012 to 2016, she acted as the clinical consultant to the project team to move the transplant database into the hospital electronic health record. In 2016 Cathy retired from full time work but continues in a casual position with the University of Minnesota transplant program as a management consultant, as well as a casual position as a research nurse with the University of Minnesota Department of Surgery. C.A.G. holds a certification as a transplant coordinator and is active in NATCO, The Organization of Transplant Professionals where she has chaired educational programs, served on the Board of Directors including the role of President in 2008 to 2009. She is also a member of the International Transplant Nurse Society, AST and ASTS. C.A.G. is an original member of the Advisory Committee for the National Living Donor Assistance Center and continues to serve on that committee. Employment: University of Minnesota, UMMC-Fairview. Speaker: ROSE Conference.
S.G. is a senior consultant transplant surgeon at the Indraprastha Apollo Hospital, New Delhi and leads one of the busiest kidney transplant programs in the world. S.G. was previously Professor of Surgery at the All India Institute of Medical Sciences where he also obtained his Masters in Surgery. He received further training in transplantation in the UK. S.G. was actively involved in setting up a live donor pediatric transplant program and has pioneered Kidney Pancreas transplant in the subcontinent. He was also involved in introducing the mini-donor nephrectomy for living donors. S.G. has also been involved in making transplant affordable and this has included pathbreaking trials using generic immunosuppression. S.G. has been the past secretary of the Indian Society of Organ transplantation as well as a member of the ethics Committee of the Transplantation Society. He is the currently coeditor of the Indian Journal of Transplantation. His current areas of interest include ABOi transplants and transplantation in sensitized recipients. S.G. has authored more than 106 publications and has given 6 orations. Advisory Board: Roche, Sanofi, Panacea Biotec, Emcure Pharmaceuticals. Grants: Novartis.
B.L.K. obtained his undergraduate training at Michigan State University, East Lansing, Michigan. He later received his medical degree from the University of Iowa, Iowa City, Iowa and completed Internal Medicine residency, and fellowship training in Nephrology at Hennepin County Medical Center, an affiliate hospital of the University of Minnesota in Minneapolis. Dr. Kasiske is former Deputy Director of the United States Renal Data System, former Editor-in-Chief of the American Journal of Kidney Diseases, and former cochair of KDIGO. Currently he is Director of Nephrology at Hennepin County Medical Center and Professor of Medicine at the University of Minnesota. He is the Principal Investigator for a NIH grant to study long-term outcomes in living kidney donors (ALTOLD). B.L.K. is also the Director of the Scientific Registry of Transplant Recipients (SRTR), which is the Federal registry of all solid organ transplants in the United States. Advisory Board: Litholink/Labcorp. Speaker: Merck Japan.
A.S.L. is Dr. Gerald J. and Dorothy R. Friedman Professor of Medicine at Tufts University School of Medicine and Chief of the William B. Schwartz, MD Division of Nephrology at Tufts Medical Center. His research is mainly in the areas of epidemiology of CKD and CVD in CKD; trials to slow the progression of CKD; clinical assessment of kidney function; assessment and improvement of outcomes in dialysis and transplantation; and clinical practice guideline development and implementation. A.S.L. was Chair of the National Kidney Foundation (NKF) Task Force on CVD in Chronic Renal Disease (1999), Chair of the Kidney Disease Outcomes Quality Initiative (KDOQI) Work Group on CKD: Evaluation, Classification and Stratification (2002), Chair of the KDOQI Work Group on Hypertension and Antihypertensive Agents in CKD (2004), and member of the KDIGO Work Group on AKI Guideline (2011) and KDIGO Work Group on CKD Guideline (2013). A.S.L. has been Program Director for an National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)-funded clinical research training program, “Clinical Trials, Epidemiology and Outcomes Research in Nephrology” since 1999 and was Editor-in-Chief for the American Journal of Kidney Diseases from 2007 to 2016. Immediate-Past Editor, American Journal of Kidney Diseases*. Grant/Research Support: NIH, NKF, Gilead, Pharmalink, Siemens. *monies paid to institution.
P.K-T.L. is the Chief of Nephrology and Consultant Physician of the Department of Medicine and Therapeutics at the Prince of Wales Hospital (PWH), Hong Kong. He is also the Honorary Professor of Medicine at the Chinese University of Hong Kong. Professor Li is the President of Asian Pacific Society of Nephrology and was the President of International Society for Peritoneal Dialysis (2014-2016). He is also the President of the International Association of Chinese Nephrologists (IACN) and cochair of International Steering Committee for World Kidney Day. P.K-T.L. also serves as the Executive Committee Member of the Asian Forum for CKD Initiatives and was the Past Chairman of the Hong Kong Society of Nephrology and Past President of the Hong Kong Transplantation Society. He has served on the Council and the Executive Committee of the International Society of Nephrology (ISN) from 2005 to 2011, and as a board member for KDIGO from 2006 to 2015. Presently he is the President of the Hong Kong College of Physicians and Chairman of the Central Renal Committee of Hospital Authority of Hong Kong. Professor Li has been a Visiting Professor to Nanjing University, Fudan University, Peking University, China; Nagoya University, Japan; and Brown University, United States. Professor Li has published over 510 original and review articles in peer-reviewed journals, 4 books and 20 book chapters and he has given over 170 lectures in international congresses, meetings and academic institutions globally. P.K-T.L. reported no relevant financial relationships.
D.L.S. is the Marjory K. and Thomas Pozefsky Professor of Surgery and Epidemiology and Associate Vice Chair of Surgery at Johns Hopkins University. With a graduate degree in biostatistics, he focuses on novel statistical and mathematical methods for simulation of medical data, analysis of large healthcare datasets, and outcomes research. D.L.S. was the first to demonstrate the survival benefit of incompatible kidney transplantation, the first to estimate attributable risk of end-stage renal disease in live kidney donors, and is responsible for the first HIV-to-HIV transplants in the United States. His NIH-funded research includes kidney exchange, desensitization, long-term donor risk, access to transplantation, expanding transplantation including HIV-positive donors, geographic disparities, and the intersection between transplantation and gerontology. D.L.S. received the AST’s Clinical Science Investigator Award and he is a councilor of the ASTS and former chair of the American Transplant Congress. His work has directly influenced policy, including 2 Congressional bills (the Norwood Act for kidney exchange and the HOPE Act for HIV-to-HIV transplants). D.L.S. is most inspired by his role as a mentor, having mentored over 65 students, residents, and faculty, and is the only general surgeon in the United States funded by an NIH/NIDDK Mentoring Grant. D.L.S. reported no relevant financial relationships.
S.J.T. is a Professor of Medicine at Mayo Clinic in Rochester, Minnesota where she is a Staff Consultant in the Division of Nephrology and Hypertension. A graduate of Mayo Medical School, she completed her Internal Medicine Residency at Hennepin County Medical Center, Minneapolis, Minnesota followed by fellowships in Hypertension and Nephrology at Boston University Medical Center, Boston, Massachusetts. She joined the staff at Mayo Clinic in 1988. S.J.T. has 28 years of experience in the treatment of complex hypertension and 15 years of experience in the care of kidney transplant recipients and donors. She has published more than 72 articles and book chapters in nephrology and hypertension and she is active in the areas of hypertension guidelines, living donor follow-up, transplant hypertension and resistant hypertension. S.J.T. has been actively involved in hypertension education at Mayo Clinic and at the national level. S.J.T. reported no relevant financial relationships.
K.T. is Professor and Chairman of Department of Urology at Tokyo Women’s Medical University and the Director of the Tokyo Women’s Medical University Hospital (TWMUH) at Tokyo, Japan. K.T. earned his MD degree from Kyushu University at Fukuoka Japan, and also completed Urology residency and Transplant clinical fellowship at Tokyo Women’s Medical University. He also completed a research fellowship in Urologic Oncology at Cleveland Clinic Foundation in Ohio, United States. K.T. served for 30 years as the transplant surgeon and urologist of TWMUH kidney transplant program where he performed more than 2000 cases of living kidney transplantation. K.T. is one of the pioneers of ABOi kidney transplantation in the world and devoted to the development of simpler, easier and safer immunosuppressive protocols for ABOi kidney transplantation and to make them as routine kidney transplant procedures. K.T. is also a clinical scientist whose research interests include surgical aspects of living kidney donation and transplantation, pediatric kidney transplantation, and desensitization of sensitized or ABOi kidney transplant patients. He is also a basic scientist in the field of transplant immunology and recently his team established a new central tolerance inducing protocol without any significant adverse events and sought to apply it in large animals. He has authored more than 300 peer reviewed publications and currently serves as a Deputy Editor of Transplantation. Presently he is an executive member of the Japanese Society of Transplantation and the Society of the Clinical Kidney Transplantation. Grants: Astellas*. Speaker: Astellas; Chugai Pharmaceutical Co. *monies paid to institution.
L.W. is Assistant Professor in the Department of Surgery, Faculty of Medicine and a member of the Joint Centre for Bioethics at the University of Toronto. L.W. is a researcher with the Canadian National Transplant Research Programme. Her primary research focus is on the ethical issues raised by organ tissue donation transplantation. She lectures nationally and internationally on this subject, has authored 16 book chapters and 36 peer reviewed articles in academic journals. L.W. reviews for several medical bioethics journals and is ethics section editor of Progress in Transplantation. L.W. is also a member of the ethics committees of the Canadian Society of Transplantation and of Canadian Blood Services and cochair of the ethics committee of Ontario’s Trillium Gift of Life Network. L.W. holds degrees in Sociology (Liverpool University, England), Social Work (McGill University, Montreal) and Bioethics (University of Toronto) and a fellowship in Bioethics from Mount Sinai Hospital and the Joint Centre for Bioethics, University of Toronto. Before her career in Bioethics, L.W. worked as a social worker in childcare and medical settings. L.W. retired in December 2015 from her position as Director of Bioethics for the University Health Network, Toronto where she led the Bioethics programme for 12 years. Since that time, Linda continues her research, teaching and committee activities. Ms. Wright reported no relevant financial relationships.
M.G.Z. is an Associate Professor and a renal physician and Head of Division of Nephrology at Heidelberg University Hospital since 2004. He started his career at Division of Nephrology in 1985 and is a specialist for kidney diseases, CVD and treatment of hypertension. His main scientific interest has been on kidney transplantation, including transplantation of high immunized patients, ABOi transplantations and immunosuppressive treatment. Since 1985 M.G.Z. has given lectures on kidney diseases at the University of Heidelberg and has authored more than 400 scientific publications in peer reviewed journals as well as a contributor to several book chapters. Grant/Research Support: Dietmar Hopp Stiftung Else Kröner Fresenius Stiftung. Speaker: Verband Deutsch Niereuzentrena Deutsche Hypertonic Akademie. Manuscript Preparation: Springer Medizin Verlag GMBH.
KDIGO Chairs: D.C.W. is Professor of Kidney Medicine at University College London, United Kingdom, and Honorary Consultant Nephrologist at the Royal Free London NHS Foundation Trust. He is a clinician scientist with an interest in the complications of CKD, specifically those that increase the burden of cardiovascular disease and/or accelerate progression of kidney failure. He has participated in the design, roll out, and monitoring of several large-scale clinical trials. D.C.W. was a member of the steering committee of the Study of Heart and Renal Protection (SHARP) and the EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE). He currently sits on the steering committee of Canaglifozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE), acting as UK principal investigator for this study. He is Clinical Lead for Division 2 of the North Thames Clinical Research Network and heads a team of 8 clinical trial nurses/practitioners at the Centre for Nephrology, Royal Free Hospital in London. D.C.W. is Past President of the UK Renal Association and past Chair of the UK Renal Registry. His other responsibilities include serving as Associate Editor of Nephrology Dialysis Transplantation and member of the Editorial Board of Journal of the American Society of Nephrology. Consultant: Akebia, Alberta Innovates Health Solutions, Amgen, AstraZeneca, Bio Nano Consulting, Boehringer Ingelheim, Bristol Myers Squibb, Fresenius, GSK, Janssen*, Otsuka, UCB Celltech, Vifor. Speaker: Amgen, Fresenius Medical Care, Janssen, Vifor Fresenius Medical Care Renal Pharma, ZS Pharma. *monies paid to institution.
W.C.W. is The Gordon A. Cain Chair of Nephrology and Professor of Medicine at Baylor College of Medicine in Houston, Texas. Dr. Winkelmayer received his medical degree (1990) from the University of Vienna, Austria, and later earned a Master of Public Health degree in Health Care Management (1999) and a Doctor of Science degree in Health Policy (2001) from Harvard University. He then spent 8 years on the faculty of Brigham and Women’s Hospital and Harvard Medical School, where he established himself as a prolific investigator and leader in the discipline of comparative-effectiveness research as it pertains to patients with kidney disease. From 2009 to 2014, he was the Director of Clinical Research in the Division of Nephrology at Stanford University School of Medicine, Palo Alto, California. He assumed his current position as Chief of Nephrology at Baylor College of Medicine in September 2014. His main areas of research interest include comparative effectiveness and safety research of treatment strategies in anemia as well as of various interventions for cardiovascular disease in patients with kidney disease. His clinical passion lies in providing quality kidney care to the predominantly disadvantaged and un(der)insured population in the public safety net health system of Harris County, Texas. W.C.W. has authored over 270 peer-reviewed publications, and he has a particular interest in medical publishing. He currently serves as an Associate Editor for The Journal of the American Medical Association, was a coeditor of the American Journal of Kidney Diseases from 2007 to 2016, and has been appointed to several other editorial boards of leading nephrology and epidemiology journals. He also volunteers his time towards important initiatives of the American Society of Nephrology (eg, Public Policy Board). He joined KDIGO volunteer leadership as an Executive Committee member in 2015 and has served as its cochair since 2016. Advisory Board: Akebia, AMAG Pharmaceuticals, Amgen, AstraZeneca, Bayer, Daichi Sankyo, Medtronic, Relypsa, Vifor Fresensius Medical Care Renal Pharma. Consultant: Akebia, AMAG Pharmaceuticals, Amgen, AstraZeneca, Bayer, Daichi Sankyo, Medtronic, Relypsa, Vifor Fresensius Medical Care Renal Pharma.
Evidence Review Team: T.J.W. is Professor of Medicine, staff member at the Minneapolis Veterans Administration (VA), and Core Investigator in the Minneapolis VA Center for Chronic Disease Outcomes Research. He is also the Director of the VA Evidence Synthesis Program at the Minneapolis VA, codirector of the Minnesota Agency for Healthcare Research and Quality (AHRQ)-Evidence-based Practice Center, and Director of the Minnesota Evidence Review Team. T.J.W. has broad clinical and research interests in chronic disease prevention and treatment, and has 2 decades of experience conducting systematic reviews. He is the founding and immediate past Editor of the Cochrane Review Group in Prostate Diseases and Urologic Cancers. T.J.W. has extensive experience working collaboratively with government and medical society guideline groups and has led prior systematic reviews used by the KDOQI clinical practice guidelines. He is also a principal investigator on numerous grants to conduct and disseminate systematic reviews across a wide spectrum of diseases. T.J.W. is a former US Preventive Services Task Force member and currently serves on the American College of Physicians Clinical Practice Guideline Committee and the VA Preventive Medicine Advisory Committee. He is a recipient of the 2014 VA Undersecretary’s Award for Excellence in Health Services Research. T.J.W. reported no relevant financial relationships.
A.I. is Associate Professor of Medicine and Chief of the Nephrology Section at the Minneapolis VA. The major focus of A.I.’s research has been in the prevention of CKD and complications associated with kidney disease. A.I. has received advanced training in systematic review methodology and has conducted numerous systematic reviews over the past 15 years in both urologic and kidney disorders, including an AHRQ-funded systematic review evaluating the benefits and harms of screening and monitoring treatment of CKD. A.I. reported no relevant financial relationships.
Y.S. is Assistant Professor of Medicine at the Minneapolis VA and the University of Minnesota. The major focus of Y.S.’s research has been in the prevention of CKD and its complications. Y.S. has received advanced training in systematic review methodology and conducted numerous systematic reviews spanning both urologic and kidney disorders. She has also participated in several NIH trials, including SPRINT and BRINK. Y.S. reported no relevant financial relationships.
M.B. reported no relevant financial relationships.
M.C. reported no relevant financial relationships.